Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Teva
UBS
Moodys
Queensland Health
QuintilesIMS
Dow
Medtronic
US Army

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050808

« Back to Dashboard

NDA 050808 describes SOLODYN, which is a drug marketed by Medicis and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug and four Paragraph IV challenges. Additional details are available on the SOLODYN profile page.

The generic ingredient in SOLODYN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Summary for 050808
Tradename:SOLODYN
Applicant:Medicis
Ingredient:minocycline hydrochloride
Patents:9
Therapeutic Class:Antibacterials
Dental and Oral Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 050808
Ingredient-typeTetracyclines
Medical Subject Heading (MeSH) Categories for 050808
Suppliers and Packaging for NDA: 050808
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808 NDA AUTHORIZED GENERIC Impax Generics 0115-9935 N 0115-9935-08
SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808 NDA AUTHORIZED GENERIC Impax Generics 0115-9936 N 0115-9936-08

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 8, 2006TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Feb 19, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Patent:➤ Try a Free TrialPatent Expiration:Jun 24, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE
Patent:➤ Try a Free TrialPatent Expiration:Mar 7, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE

Expired US Patents for NDA 050808

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-001 May 8, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Fish and Richardson
Express Scripts
Chubb
Teva
Healthtrust
AstraZeneca
US Army
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.